• Performance of immunoassays used to diagnose HIT varies substantially with regard to the specific characteristics of the tests.
Introduction
In clinical practice, immunoassays are pivotal for the work-up of patients with suspected heparin-induced thrombocytopenia (HIT) [1] [2] [3] [4] . HIT is a life-threatening complication of heparin therapy, which affects a significant number of patients 5 . It is associated with a high morbidity and mortality due to a massive pro-coagulant state, with a high incidence of extensive venous and arterial thrombosis, limb loss and even death 6, 7 . Suspicion of HIT requires an immediate diagnostic workup to prevent severe complications 1, 8, 9 . Still, diagnosis of HIT is challenging 1, 10 .
Functional assays, such as the serotonin release assay (SRA) or the heparin-induced platelet activation assay (HIPA) are accepted as gold standard, but are rarely available in a timely manner 2, 3, 11 . Clinical assessment tools such as the 4T's score can exclude HIT in many patients if conducted by experienced observers 12 . However, the positive predictive value is low 12 , they are subject to a relevant inter-observer variability 13 , and they are not adequately evaluated in all settings 14 . To make a treatment decision at bedside, physicians are recommended by current guidelines and recent reviews to order an HIT immunoassay in all patients with an intermediate or high risk 4T's score 1, 8, [10] [11] [12] 15 .
Many tests and several classes of assays have been developed by a number of manufacturers.
They recognize different classes of antibodies, utilize varying thresholds and may apply test variations such as the high-dose heparin confirmation step. All tests are based on detecting antibodies targeting complexes of platelet factor 4 (PF4) bound to heparin (or other polyanions respectively) 16, 17 . A solid-phase enzyme-linked immunosorbent assay (ELISA) using a low optical-density threshold (OD) and targeting IgG-, IgM and IgA-antibodies was already developed in the mid 90ies 16, 18 . Later on, other tests were introduced: IgG-specific assays 19 , high-and intermediate OD thresholds 19, 20 , as well as the high-dose heparin confirmation step 21 .
Other classes of assays have been developed to enable short turnaround times and a 24-hourservice: particle gel immunoassay (PaGIA), particle immunofiltration assay (PIFA), lateral flow immunoassay, latex agglutination assay and chemiluminescent immunoassay (CLIA). Different antibody specificities are available for the CLIA and a number of thresholds have been proposed for CLIA and PaGIA. The corresponding diagnostic accuracy studies are hard to interpret because of varying results, imprecise estimates and sometimes conflicting data. In clinical practice, it is difficult to choose the right assay because it remains unclear, if and how the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From mentioned test characteristics influence the diagnostic value. Several authors raised concerns that the diagnostic value may differ relevantly among the individual tests 2, [22] [23] [24] . As a result of this uncertainty, the application of assays varies greatly among laboratories 25 .
The aim of the present investigation was to assess the diagnostic accuracy with regard to different classes of assays, antibody specificities, thresholds, manufacturers, application of highdose heparin confirmation step, and material used. In addition, we assessed whether different reference standards used in diagnostic accuracy studies have an impact on the diagnostic accuracy. We retrieved all available data, applied strict inclusion criteria, systematically assessed methodological quality, and pooled diagnostic accuracy measures if possible.
Methods
Before start of the investigation, we developed a research protocol according to recommendations of the Cochrane Diagnostic Test Accuracy Working Group 26 .
Study identification
A search strategy was developed for MEDLINE, EMBASE and Cochrane Collaboration databases to identify diagnostic accuracy studies of immunoassays for diagnosis of HIT (see supplemental data). Search strategy was refined using keywords of references found in a pilot search, and after manual review of reference lists. Search strategy was tested in 12 index publications (100 percent sensitivity). Literature search was supplemented by manual review of reference lists, including the ACCP antithrombotic practice guideline (ninth edition) 2 . No restrictions or filters with regard to language, publication date and age range were applied. Last search run was conducted on 2 nd of November 2014. Records were screened by two investigators (MN, ATC); all hits were assessed in full-text for eligibility.
Study eligibility
The following inclusion criteria were applied: (1) evaluation of a commercially available or fully described immunoassay to detect Heparin/PF4 antibodies, (2) application of the index test to patients with suspected HIT, (3) application of a reference standard that is established or fully described, (4) numbers of true positives, false positives, true negatives and false negatives are reported or can be calculated. We considered a reference standard test to be established if it is evaluated in reasonably designed studies and implemented in routine practice. Studies were studies that compare diagnostic accuracy of one immunoassay with another one without using an established reference standard. Two reviewers assessed eligibility and consensus was achieved by discussion (MN, AtC; raw agreement 0.91; Cohen's kappa 0.71).
Data extraction
Included studies were reviewed in duplicate and the following data were extracted: author, year of publication, study design, type of patient selection, characteristics of study population including cohort criteria, inclusion procedure, setting, characteristics of index test including antibody specificity, thresholds, material used, and use of high-dose heparin confirmation test, application of index test, characteristics of reference standard, application of reference standard, sample size, disease prevalence, numbers of true positives, false positives, true negatives and false negatives (reported or calculated). Test results were categorized according to the "intention-to-diagnose" principle to avoid biased overestimation of diagnostic accuracy 27 :
inconclusive results of the index test were classified as negative if the reference standard was positive, and rated as positive if the reference standard was negative 27 . Observations were excluded from analysis if the reference standard revealed inconclusive results. For example, in one study an inconclusive PIFA result was classified as negative because SRA was positive, another inconclusive PIFA result was counted as positive because SRA was negative, and two observations were excluded because of a borderline SRA result in combination with a negative ELISA and a low 4T score
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. Two-by-two tables were created for every evaluation study.
Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and pre-test probability (prevalence) were calculated. 
Assessment of methodological quality
The methodological quality of the individual studies was assessed in terms of risk of bias and concerns regarding applicability using the revised tool for quality assessment of diagnostic accuracy studies (QUADAS-2). Details of this validated and widely accepted instrument are published elsewhere 29 . Shortly, methodological quality is assessed in four domains (patient selection, index test, reference standard, flow and timing) by the use of signaling questions.
According to the published guidelines, we adjusted the signaling questions to our particular research questions and developed detailed decision criteria. In a pilot study, the adapted QUADAS-2 tool was applied to a subset of 7 studies by two investigators (MN, ATC) with a good agreement. Signaling questions and decision criteria were refined after these pilot studies to further improve reliability. Application of adapted QUADAS-2 tool to all included studies was done in duplicate and disagreement was solved by discussion between two investigators.
Statistical analysis
To assess the diagnostic accuracy of different classes of assays, we grouped observations by class, antibody specificity, threshold, and the use of the high-dose heparin confirmation step. In addition, we considered differences in ELISA assay designs by grouping according to manufacturer, antibody specificity, threshold, and use of the high-dose heparin confirmation step. To observe the impact of different reference standards used in evaluation studies, we conduced a stratified analysis in the assay class with the most available studies and performed a meta-regression analysis (see below). To maintain independency of observations, studies which were conducted in the same study population were included only once in each group. In these cases, we selected the study to be included according to the following priorities: 1.) largest number of observations, 2.) type of manufacturer that was included less often within the particular category. As heterogeneity is expected to be high in systematic reviews of diagnostic accuracy studies, we followed current recommendations and did not 
Results

Study identification and selection
Literature search yielded 2716 records, including 2 publications identified by manual review (Figure 1 ). 
Study characteristics
Detailed characteristics of all 128 diagnostic accuracy studies are given in 
Methodological quality
A summary of the methodological quality is shown in Figure 2 , the quality of the individual studies is reported in Figure S1 of the supplemental data. A low risk of bias in all four domains was observed in 2 out of 128 evaluation studies only (1.6%) 68 . The median number of low-risk ratings was 1 (25%). A high risk of bias was assessed in 125 cases (24.4%). Most high-risk ratings were assigned in the domain patient selection (57) and the fewest in index test (11) . Most low-risk ratings were found in the reference standard domain (90). In contrast, low concerns regarding applicability were assessed in 276 cases (71.9%). Methodological criteria that were frequently inadequately addressed were (1) prospectively enrolled patients, (2) specified cohort criteria, (3) numbers and reasons for excluded patients, (4) interpretation of reference standard without knowledge of the index test, and (5) clearly described sequence of testing.
Diagnostic accuracy of immunoassay classes -HSROC and bivariate model
We were able to calculate diagnostic accuracy measures according to the unified model for nine Table 2 and in Figure 5 (assuming constant likelihood ratios).
Approximate diagnostic accuracy of immunoassay classes -fixed effects model
Because of a limited number of studies, we were unable to calculate diagnostic accuracy measures using the unified model in 9 tests: polyspecific ELISA and IgG-specific ELISA with high threshold, polyspecific ELISA and IgG-specific ELISA with high-dose heparin Table 2 . Sensitivity was below 95% in all of the above-mentioned tests except poly-ELISA with low threshold and high heparin-dose confirmation step.
Diagnostic accuracy of ELISA assays by manufacturer
We were able to calculate diagnostic accuracy measures for the individual ELISA manufacturers by means of the unified model in 8 assays and by the use of a fixed effects model in two assays.
No pooling was possible in four assays with a unique evaluation study. Results are reported in Table 3 . In most of the assays, diagnostic accuracy corresponds to the general characteristic of the class (sensitivity above or below 95%, specificity above or below 90%). However, some assays appear to be inferior (e.g. IgG-specific Asserachrom assay with a low threshold). 
Potential sources of heterogeneity and bias
For the first sensitivity analysis, calculations were repeated in studies with cohort designs only (lower risk of bias). Only minor differences were observed (range 0.0 to 0.5% for sensitivity, and 0.0 to 3.6% for specificity), the results are shown in Table S2 of the supplementary data. In the second sensitivity analysis, data of studies that used SRA/HIPA as reference standard were pooled only (Table S5 of the supplementary data) and compared with results from all studies.
Differences ranged between 0.2 and 1.7% for sensitivity, and 0.7 and 1.5% for specificity. Third, we compared data of different tests obtained within the same study population using the same reference standard. Table S4 of the supplemental data shows the results of the two populations with the most tests evaluated. The results of the individual studies and the differences between different categories (thresholds, antibody specificity, class of assays) correspond very well with the pooled data. Table S3 of the supplemental data shows results of a meta-regression analysis exploring the impact of the reference standard used, setting, as well as specimen material on diagnostic accuracy. No significant results were observed for any of the above-mentioned variables.
In general, neither sensitivity analyses nor meta-regression recognized any characteristic of study design as possible source of heterogeneity and bias.
Discussion
Key findings
Important differences exist between classes of immunoassays, type of antibodies, thresholds, and application of confirmation step, and only five tests appear optimal for clinical use. Relevant variations were found even between manufacturers of ELISA assays. In general, methodological quality of primary studies was moderate. Nevertheless, the results were consistent and no differences were found in sensitivity analyses.
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Strengths and limitations
The present investigation is the first systematic review and meta-analysis focusing on immunoassays for diagnosis of HIT. We conducted a comprehensive literature search to retrieve the published evidence, applied strict inclusion criteria, assessed the methodological quality of the studies systematically, and used an appropriate meta-analytic technique to pool the existing data. Thus, we were able to compare diagnostic accuracy measures between classes of assays, manufacturers, antibody specificities, thresholds and the application of high-dose heparin confirmation step.
Our study has several limitations. First, methodological quality of primary studies was only moderate in general. Even though we cannot fully exclude that this might have influenced our results, we estimate the risk to be low: (1) applying strict inclusion criteria, we excluded 94 publications because of low quality, (2) sensitivity analysis did not show relevant differences if compared with high-quality publications only, and (3) the results were consistent across subgroups. Second, the number of available studies was limited in certain categories of tests, restricting the analysis to a fixed effects meta-analytic model only (Table 2 and 3) . The results of this analysis must be interpreted with caution, because it is not accepted as a valid statistical technique in this situation. The number of studies and cases is even more limited in certain categories. For example, the favorable sensitivity of poly-ELISA with low threshold and high heparin-dose confirmation step largely depends on one study in which the only one HIT case was detected (corresponding to a sensitivity of 100%) 67 . The number of studies and patients is limited even for the tests most investigated, leading to a restricted precision with wide confidence intervals. For example, expected differences between polyspecific and IgG-specific ELISA in terms of sensitivity and specificity could not be reproduced in every subgroup (Table   2) . And third, a number of different reference standard tests have been used in evaluation studies and we cannot fully preclude that this might have influenced the results of our investigation.
However, we expect the risk to be low for several reasons: (1) a sensitivity analysis comparing diagnostic accuracy measures obtained with one of the accepted gold standards SRA/HIPA only and all results did not find any difference, (2) meta-regression analysis revealed no difference in diagnostic odds ratio if SRA/HIPA were compared to other defined reference standard tests,
we applied strict inclusion criteria requiring a clear definition of reference standard tests, and (4) One may argue that a systematic review of diagnostic tests for HIT should focus on sensitivities and specificities. Indeed, sensitivity and specificity are well-known (even though often misinterpreted) measures of diagnostic accuracy, and reporting them is essential. However, the important question in clinical practice is, how a particular test result predicts disease and sensitivities/specificities cannot answer this question. Predictive values are often used, but these measures depend on the prevalence of the disease and generalization beyond a study population is difficult 80 . Likelihood ratios are powerful diagnostic accuracy measures because they are assumed to be independent from prevalence, they express how many times more (or less) likely a test result is in patients with the disease in contrast to patients without the disease, and they can be used to calculate post-test probabilities. In addition, differences in likelihood ratios between tests can be seen clearly in a forest plot. In contrast, it is hard to read a forest plot with estimates of sensitivities or specificities along with confidence intervals when most data are between 90 and 100% (ceiling effect). Following these considerations, we decided to report all sensitivities/specificities in a table and likelihood ratios as a forest plot.
Implications for clinical practice
With the present investigation, we provide aggregated diagnostic accuracy measures for all frequently applied immunoassays used to diagnose HIT. Our results will raise the clinicians' awareness for the characteristics of tests they are confronted with. Using the post-test probabilities provided in Table 2 and Figure 5 , clinicians may be enabled to estimate the probability of HIT in individual patients. If used in combination with clinical scoring systems (which assess the pre-test probability), they might improve care in patients with suspected HIT substantially. In addition, laboratory managers can use our results to compare test characteristics directly, and base decisions about which test to implement on a sound scientific background.
Implications for future research
No antibody test is both 100% sensitive and specific and such a test is not expected in the near future. Functional assays are rarely available in a timely fashion. Clinical scoring systems such as the 4T's score could help identifying patients with a low pre-test probability and might reduce the number of "overtreated" patients 12 . However, there are several unsolved issues associated 
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Van Hoecke F, Devreese K. Evaluation of two new automated chemiluminescent assays (HemosILAcuStar HIT-IgG and HemosILAcuStar HIT-Ab) for the detection of heparin-induced antibodies in the diagnosis of heparin-induced thrombocytopenia. * below or equal to OD 0.7; + between OD 0.8 and 1.4; # above OD 1.4; ° positive/negative; § titer 2 to 3; † 1.0 U/ml; between 1.0 and 2.8 U/ml; ‡ above 2.8 U/ml; ** above 3.85 U/ml; + in tests with < 4 studies available, summary estimates were calculated using a fixed-effects model (Mantel-Haenszel method) -however, the results of this analysis must be interpreted with caution, because it is not accepted as a valid statistical technique in this situation; ° only one study available; # result of fixed effects model appears invalid because the favorable sensitivity depends on one study in which the only one HIT case was detected 67 For personal use only. * Studies which were conducted in the same study population were included only once to maintain independency of observations; + in tests with < 4 studies available, summary estimates were calculated using a fixed-effects model (Mantel-Haenszel method; to be interpreted with caution); # including technically identical Gen-Probe assay; ° application of pooled 'in-house assay' data to individual tests must be done with caution because these tests are constructed differently (every assay must be evaluated individually) 
